Merck doses first patient in Phase 3 trial of novel antibody-drug conjugate for metastatic colorectal cancer
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
